14.8 C
New York
Friday, April 26, 2024
HomeMarkets
Markets

Synergy Reports Positive Phase 3-Trial 1 Data

By Insider Scoop
0
13
psw-placeholder
psw-placeholder

Courtesy of Benzinga.

Synergy Reports Positive Phase 3-Trial 1 Data

Before Friday’s market open, Synergy Pharmaceuticals Inc (NASDAQ: SGYP) announced positive data from its first of two Phase 3 trials for clinical constipation-predominant irritable bowel syndrome (IBS-C) drug plecanatide.

“We are very pleased with these results,” said Gary S. Jacob, Ph.D., chairman and CEO of Synergy. “These data reinforce our strong belief that plecanatide may represent an important new treatment option for the millions of patients currently suffering from IBS-C. We look forward to the results of our second phase 3 IBS-C trial with plecanatide later this month.”

If the second Phase 3 results show positive data as well, an NDA should be filed in Q1 2017, and the FDA should be expected to make a decision by January 29, 2017, according to BTIG analyst Timothy Chiang.

At last check, shares of Synergy were trading up 17 percent in the pre-market session.

Latest Ratings for SGYP

Date Firm Action From To
May 2016 Rodman & Renshaw Maintains Buy
Mar 2016 Rodman & Renshaw Maintains Buy
Mar 2016 Citigroup Maintains Neutral

View More Analyst Ratings for SGYP


View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News FDA Analyst Ratings Movers Trading Ideas General Best of Benzinga

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,318FansLike
396,312FollowersFollow
2,290SubscribersSubscribe

Latest Articles

Load more

Note: The material presented in this commentary is provided for informational purposes only and is based upon information that is considered to be reliable. However, neither PSW Investments, LLC d/b/a PhilStockWorld (PSW) nor its affiliates warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither PSW nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance, including the tracking of virtual trades and portfolios for educational purposes, is not necessarily indicative of future results. Neither Phil, Optrader, or anyone related to PSW is a registered financial adviser and they may hold positions in the stocks mentioned, which may change at any time without notice. Do not buy or sell based on anything that is written here, the risk of loss in trading is great.

This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only intended at the moment of their issue as conditions quickly change. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.

Contact us: support@philstockworld.com

© Copyright - PSW, LLC.

2024
0
Would love your thoughts, please comment.x
()
x